Various Adverse Effects and Behaviors Associated with Sildenafil;Another Case of Glycemic Control Problems Associated with Fluoroquinolone Therapy;The First Case of Pure White Cell Aplasia in a Patient Treated with Imipenem–Cilastatin;High-Output Heart Failure Associated with Anagrelide;Renal Dysfunction Attributed to Oral Acyclovir Therapy;Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy – Reiterating the Importance of Reporting Adverse Events;A Final Note on Medication Adherence
Restricted accessOtherFirst published online October, 2005
Various Adverse Effects and Behaviors Associated with Sildenafil;Another Case of Glycemic Control Problems Associated with Fluoroquinolone Therapy;The First Case of Pure White Cell Aplasia in a Patient Treated with Imipenem–Cilastatin;High-Output Heart Failure Associated with Anagrelide;Renal Dysfunction Attributed to Oral Acyclovir Therapy;Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy – Reiterating the Importance of Reporting Adverse Events;A Final Note on Medication Adherence
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.
Get full access to this article
View all access options for this article.
References
1.
KimB.J., RheeP.L., SonH.J.Sildenafil prescribed for erectile dysfunction may induce esophageal symptoms. J Clin Gastroenterol.2005; 39(7): 643–644.
2.
KekilliM., BeyazitY., PumakT.Acute myocardial infarction after sildenafil ingestion. Ann Pharmacother.2005; 39(7): 1362–1364.
3.
SwearingenS.G., KlausnerJ.D.Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection. Amer J Med.2005; 118(6): 571–577.
4.
AlpertJ.S.Viagra: the risks of recreational use. Amer J Med.2005; 118(6): 569–570.
5.
ShusterJ.ISMP adverse drug reactions. Hosp Pharm.2005; 40(7): 562.
6.
BlommelA.L., LutesR.A.Severe hyperglycemia during renally adjusted gatifloxacin therapy. Ann Pharmacother.2005; 39(7): 1349–1352.
7.
KalambokisG., VassouA., BourantasK.Imipenum-cilastatin induced pure white cell aplasia. Scand J Infect Dis.2005; 37(8): 619–620.
8.
EngelP.J., JohnsonH., BaughmanR.P.High-output failure associated with anagrelide therapy for essential thrombocytosis. Ann Int Med.2005; 143(4): 311–313.
9.
YavuzB.B., CankurtaranM., HalilM.Renal dysfunction after oral acyclovir in a geriatric woman: a case report. Scand J Inf Dis.2005; 37(8): 611–613.
10.
Van AsscheG., Van RanstM., SciotR.Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med.2005; 353(4): 362–268.
11.
Kleinschmidt-DeMastersB.K., TylerK.L.Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med.2005; 353(4): 369–374.
12.
Langer-GouldA., AtlasS.W., GreenA.J.Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med.2005; 353(4): 375–381.
13.
BergerJr, KoralnikI.J.Progressive multifocal leukoencephalopathy and natalizumab – unforeseen consequences. N Engl J Med.2005; 353(4): 414–416.
14.
AdelmanB., SandrockA., PanzaraM.A.Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med.2005; 353(4): 432–433.
15.
DrazenJ.M.Patients at risk. N Engl J Med.2005; 353(4): 417.
16.
ShusterJ.ISMP adverse drug reactions. Hosp Pharm.2005; 40(8): 657.
17.
OsterbergL., BlaschkeT.Adherence to medication. N Engl J Med.2005; 353(5); 487–497.
